TABLE 2.
AUC (95% CI) | SN | SP | PPV | NPV | |
---|---|---|---|---|---|
Total sample without covariates (47 Aβ‐PET negative vs. 58 Aβ‐PET positive) | |||||
Aβ42/40 | 0.750 (0.655–0.845) | 0.690 | 0.766 | 0.784 | 0.667 |
pTau181 | 0.895 (0.832–0.959) | 0.879 | 0.809 | 0.850 | 0.844 |
NfL | 0.493 (0.367–0.619) | 0.931 | 0.319 | 0.628 | 0.789 |
GFAP | 0.772 (0.678–0.866) | 0.862 | 0.596 | 0.725 | 0.778 |
TabCAT‐BHA | 0.700 (0.602–0.799) | 0.345 | 1.000 | 1.000 | 0.553 |
Total sample with covariates a (45 Aβ‐PET negative vs. 56 Aβ‐PET positive) | |||||
Aβ42/40 | 0.886 (0.824–0.948) | 0.679 | 0.933 | 0.927 | 0.700 |
pTau181 | 0.933 (0.885–0.980) | 0.804 | 0.933 | 0.938 | 0.792 |
NfL | 0.864 (0.793–0.935) | 0.786 | 0.822 | 0.846 | 0.755 |
GFAP | 0.895 (0.835–0.956) | 0.875 | 0.778 | 0.831 | 0.833 |
TabCAT‐BHA | 0.918 (0.866–0.971) | 0.893 | 0.844 | 0.877 | 0.864 |
SCI and MCI only without covariates (32 Aβ‐PET negative vs. 38 Aβ‐PET positive) | |||||
Aβ42/40 | 0.790 (0.683–0.898) | 0.711 | 0.813 | 0.818 | 0.703 |
pTau181 | 0.888 (0.808–0.967) | 0.921 | 0.750 | 0.814 | 0.889 |
NfL | 0.527 (0.373–0.681) | 0.921 | 0.344 | 0.625 | 0.786 |
GFAP | 0.772 (0.659–0.886) | 0.789 | 0.656 | 0.732 | 0.724 |
TabCAT‐BHA | 0.642 (0.513–0.772) | 0.474 | 0.781 | 0.720 | 0.556 |
SCI and MCI only with covariates a (31 Aβ‐PET negative vs. 36 Aβ‐PET positive) | |||||
Aβ42/40 | 0.927 (0.867–0.986) | 0.806 | 0.935 | 0.935 | 0.806 |
pTau181 | 0.939 (0.883–0.995) | 0.806 | 0.968 | 0.967 | 0.811 |
NfL | 0.883 (0.798–0.967) | 0.889 | 0.774 | 0.821 | 0.857 |
GFAP | 0.913 (0.843–0.983) | 0.889 | 0.839 | 0.865 | 0.867 |
TabCAT‐BHA | 0.883 (0.805–0.960) | 0.667 | 0.935 | 0.923 | 0.707 |
Abbreviations: Aβ‐PET, amyloid β positron emission tomography; APOE, apolipoprotein E; AUC, area under the ROC curve; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; NfL, neurofilament light; NPV, negative predictive value; PPV, positive predictive value; SCI, subjective cognitive impairment; SN, sensitivity; SP, specificity; TabCAT‐BHA, Tablet‐based Cognitive Assessment Tool Brain Health Assessment.
Covariates include age (years), sex (female), education (years), presence of APOE 𝜀4 allele (binary), and time difference between PET acquisition and plasma collection (days).